{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:50:58Z","timestamp":1791280258126,"version":"4.1.0"},"reference-count":14,"publisher":"American Association for Cancer Research (AACR)","issue":"15","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Purpose: Various immune systems play important roles in the clinical efficacy of intravesical Bacillus Calmette-Guerin (BCG) instillation for bladder cancer. However, human leukocyte antigen (HLA) class I molecules on tumor cells and various immune system cells infiltrating to\/around the tumor have not been evaluated, although many prognostic factors, including clinical, pathologic, and molecular ones, have been investigated. The aim of this study was to determine immunologic prognostic factors of BCG immunotherapy for bladder cancer.<\/jats:p>\n               <jats:p>Experimental Design: Immunohistochemical staining for HLA class I, CD4, CD8, CD20, CD68, TIA-1, S-100, and FOXP3 was carried out on specimens from 30 patients who underwent BCG immunotherapy from whom both pretreatment and posttreatment specimens were obtained. We did univariate and multivariate analyses of factors affecting recurrence-free survival. The positive, weakly positive, and negative groups of cells that infiltrated to\/around the tumor were compared with recurrence-free survival using the Kaplan-Meier method and log-rank test.<\/jats:p>\n               <jats:p>Results: HLA class I was a significant prognostic factor both in univariate and multivariate analyses. The 5-year recurrence-free survivals of the patients with HLA class I\u2013positive tumors and those with HLA class I\u2013negative tumors were 55.7% and 19.1%, respectively (P = 0.019). There was a significant association between infiltration of CD8, CD20, and CD68-positive cells after BCG therapy and therapeutic effects.<\/jats:p>\n               <jats:p>Conclusions: Our data show that expression of HLA class I molecules on tumor cells contributes significantly to the therapeutic effect of BCG immunotherapy for bladder cancer. It is suggested that CTLs may be one of main effectors in this therapy.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-06-0595","type":"journal-article","created":{"date-parts":[[2006,8,9]],"date-time":"2006-08-09T17:02:14Z","timestamp":1155142934000},"page":"4641-4644","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Effect of Human Leukocyte Antigen Class I Expression of Tumor Cells on Outcome of Intravesical Instillation of Bacillus Calmette-Guerin Immunotherapy for Bladder Cancer"],"prefix":"10.1158","volume":"12","author":[{"given":"Hiroshi","family":"Kitamura","sequence":"first","affiliation":[{"name":"1Urology and Departments of"},{"name":"2Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Torigoe","sequence":"additional","affiliation":[{"name":"2Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiya","family":"Honma","sequence":"additional","affiliation":[{"name":"1Urology and Departments of"},{"name":"2Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Sato","sequence":"additional","affiliation":[{"name":"1Urology and Departments of"},{"name":"2Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Asanuma","sequence":"additional","affiliation":[{"name":"2Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Hirohashi","sequence":"additional","affiliation":[{"name":"2Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Sato","sequence":"additional","affiliation":[{"name":"2Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"1Urology and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2006,8,9]]},"reference":[{"key":"2022061104465920200_B1","doi-asserted-by":"crossref","unstructured":"Bevers RFM, Kurth K-H, Schamhart DHJ. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer\u20082004;91:607\u201312.","DOI":"10.1038\/sj.bjc.6602026"},{"key":"2022061104465920200_B2","doi-asserted-by":"crossref","unstructured":"Kitamura H, Tsukamoto T. Early cancers: concept, diagnosis, and management. Bladder cancer. Int J Clin Oncol\u20082006;11:28\u201337.","DOI":"10.1007\/s10147-006-0552-y"},{"key":"2022061104465920200_B3","doi-asserted-by":"crossref","unstructured":"O'Donnell MA. Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer. Urol Clin North Am\u20082005;32:121\u201331.","DOI":"10.1016\/j.ucl.2005.01.003"},{"key":"2022061104465920200_B4","doi-asserted-by":"crossref","unstructured":"Saint F, Salomon L, Quintela R, et al. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Gue\u0301rin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur Urol\u20082003;43:351\u201361.","DOI":"10.1016\/S0302-2838(03)00048-4"},{"key":"2022061104465920200_B5","doi-asserted-by":"crossref","unstructured":"Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet\u20081999;353:1689\u201394.","DOI":"10.1016\/S0140-6736(98)07422-4"},{"key":"2022061104465920200_B6","doi-asserted-by":"crossref","unstructured":"Kitamura H, Torigoe T, Honma I, et al. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy. Urology 2006;67:955\u20139.","DOI":"10.1016\/j.urology.2005.11.052"},{"key":"2022061104465920200_B7","doi-asserted-by":"crossref","unstructured":"Dalbagni G, Herr HW. Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin North Am\u20082000;27:137\u201346.","DOI":"10.1016\/S0094-0143(05)70241-X"},{"key":"2022061104465920200_B8","doi-asserted-by":"crossref","unstructured":"Hara I, Sato N, Miyake H, Muramaki M, Hikosaka S, Kamidono S. Introduction of 65 kDa antigen of Micobacterium tuberculosis to cancer cells enhances anti-tumor effect of BCG therapy. Microbiol Immunol\u20082004;48:289\u201395.","DOI":"10.1111\/j.1348-0421.2004.tb03525.x"},{"key":"2022061104465920200_B9","doi-asserted-by":"crossref","unstructured":"Bo\u0308hle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol\u20082003;170:964\u20139.","DOI":"10.1097\/01.ju.0000073852.24341.4a"},{"key":"2022061104465920200_B10","doi-asserted-by":"crossref","unstructured":"Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol\u20082002;12:3\u201313.","DOI":"10.1006\/scbi.2001.0404"},{"key":"2022061104465920200_B11","doi-asserted-by":"crossref","unstructured":"Marincola FM, Jaffee EM, Hicklin DJ, et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol\u20082000;74:181\u2013273.","DOI":"10.1016\/S0065-2776(08)60911-6"},{"key":"2022061104465920200_B12","unstructured":"Torigoe T, Nakazawa E, Asanuma H, et al. Establishment of a novel anti-pan HLA class I antibody revealed frequent down-regulation in primary and metastatic breast cancer tissues. J Transl Med. In press 2006."},{"key":"2022061104465920200_B13","doi-asserted-by":"crossref","unstructured":"Saint F, Patard JJ, Groux Muscatelli B, et al. Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Gue\u0301rin treatment. BJU Int\u20082001;88:602\u201310.","DOI":"10.1046\/j.1464-410X.2001.02394.x"},{"key":"2022061104465920200_B14","doi-asserted-by":"crossref","unstructured":"Mehmut M, Takeda K, Abe M, et al. Fas ligand and TNF-related apoptosis-inducing ligand induction on infiltrating lymphocytes in bladder carcinoma by bacillus Calmette-Gue\u0301rin treatment. Urol Int\u20082005;75:80\u20137.","DOI":"10.1159\/000085934"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/12\/15\/4641\/1922506\/4641.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/12\/15\/4641\/1922506\/4641.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T19:15:44Z","timestamp":1654974944000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/12\/15\/4641\/189478\/Effect-of-Human-Leukocyte-Antigen-Class-I"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,1]]},"references-count":14,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2006,8,9]]},"published-print":{"date-parts":[[2006,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-06-0595","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,1]]}}}